Organic Active Ingredients TRIZ Cases

Formula I compounds overcome T790M and C797S resistance by targeting non-ATP competitive sites on EGFR kinases.

Inhaled chloroquine achieves therapeutic pulmonary concentrations while reducing systemic exposure and toxicity associated with oral administration.

Rotating wheel axes allow trolleys to negotiate track intersections without entrapment.

Column chromatography separates briarane-type diterpenoids from coral extracts, increasing compound purity while reducing marine resource exploitation.

Combining Compound A with HER2 inhibitors targets cancer cells through synergistic pathway inhibition.

A cell-penetrating complex uses a pH-sensitive immolative polymer to transport nucleic acids across cellular membranes.

Crystallizing 1,25-dihydroxyvitamin D2 from acetone and water eliminates methyl formate residues that accelerate chemical degradation during storage.

Administering a heparan sulfate mimetic alongside an immune checkpoint modulator to synergistically accumulate T cells within tumor tissue.

Specific tetrahydroisoquinoline derivatives target aberrant PRMT5 expression, resolving the lack of effective therapies for sickle cell disease.

MEK, EGFR, and ERBB2 inhibitor combinations overcome feedback resistance in KRAS-mutant lung and colon cancers by synergistically blocking signaling pathways.

A conductive polymer microneedle array delivers therapeutic agents via electrical stimulation to the central nervous system.

Triazolopyridazine derivatives inhibit BRD4 protein activity, suppressing MYC pathway activation and promoting terminal differentiation in leukemia cells.

Heating TPGS above its melting point dissolves the dengue viral replication inhibitor, resolving solubility and stability contradictions.

Tetrahydrothienopyridine compounds inhibit HIF prolyl hydroxylases to modulate hypoxia-inducible factor levels.

Segmenting the molecule into a stable prodrug form and active core resolves gastrointestinal instability while enabling efficient absorption.

A pharmaceutical tablet composition uses lactose and dual disintegrants to improve dissolution consistency.

Oral di-cyclopropyl compounds replace injectable biologics to treat psoriasis and ankylosing spondylitis while maintaining therapeutic efficacy.

Bromophenol-pyrazoline compounds inhibit feline infectious peritonitis virus replication, addressing ineffective current treatments and high mortality rates.

Formula I-8 compounds modulate therapeutic efficacy and toxicity profiles through modular ring system variations.

PKR activators reduce 2,3-DPG levels to prevent hemoglobin polymerization, avoiding hydroxyurea toxicity while treating sickle cell disease.

Optimized chitosan nanoparticles maintain complex stability while achieving transfection efficiency in the harsh gut environment.

PSMA binding ligand-linker conjugates deliver therapeutic agents selectively to prostate cancer cells, sparing non-target tissues from chemotherapy damage.

Modifying molecular structures of tricyclic compounds enhances binding affinity for bromodomain proteins, overcoming limited targeting in existing therapies.

Vacuum spray precipitation dissolves carotenoids in organic solvent and precipitates them into vegetable oil to form fine particles.

Intramolecular nucleophilic attack on the 3′ phosphotriester group releases the drug while eliminating residual polymer traces.

Heterocyclic compounds inhibit ATR kinase to overcome resistance in cancers with defective cell cycle checkpoints.

Cholesterol-based microspheres stabilize lipophilic drugs, resolving toxicity risks while ensuring uniform bioavailability across animal species.

siRNA nanoparticles inhibit angiogenesis and tumor growth by down-regulating VEGFR2 and TGF-BETA1 pathways.

Chitosan-collagen composite avoids immune responses while promoting bone cell regeneration and osseointegration.

Multi-peg lipid compounds combine hydrophobic moieties with multiple polyethylene glycol chains to enhance transfection efficiency.

Anti-CD200 antibody blocks CD200-CD200R pathway to prevent rejection without nephrotoxicity.

Acridone compounds reverse parasite resistance to existing antimalarial drugs, restoring treatment effectiveness against resistant strains.

Low-dose capsaicin and etanercept regimens prevent cisplatin-induced ototoxicity by activating STAT1 survival pathways before damage occurs.

An elastomeric polymer formulation traps oxycodone within micro particles to prevent physical manipulation.

Novel compounds targeting CXCR4 and CCR5 receptors overcome tropism switching and resistance in HIV treatment.

Ciclopirox activates natural feedback loops by stabilizing heme levels, reducing toxic porphyrin accumulation in dysregulated biosynthesis.

Oxadiazolopyridine derivatives inhibit ghrelin O-acyl transferase, reducing food intake and body weight while improving glucose homeostasis.

miR-7 miRNA downregulates epidermal growth factor receptor expression, sensitizing resistant cancer cells to tyrosine kinase inhibitors.

A transdermal fentanyl solution with penetration enhancers deposits drug in the stratum corneum for systemic absorption.

A BTK inhibitor compound with specific chemical structure modifications enhances stability and bioavailability in oral dosage formulations.

Peptide amphiphile nanofibers deliver therapeutic agents to atherosclerotic lesions, reducing plaque burden and recurrence rates.

Denatonium salt activates bitter receptors to reduce liver fat accumulation and inflammation, addressing limited treatment options for NASH.

Measuring specific miRNA levels resolves the contradiction between diagnostic accuracy and early detection timing for motor neuron diseases.

Directly producing granulated compositions by absorbing APIs into porous inorganic excipient pores eliminates sticky extrudates and cryo-milling requirements.

Combining an Axl inhibitor with osimertinib targets multiple signaling pathways in solid cancers.

Selective pyrazol-4-yl-pyridine allosteric modulators target M4 receptors to treat neurological disorders without gastrointestinal side effects.

Complementary oligonucleotide sequences hybridize with ATXN2 RNA to silence toxic protein expression, addressing polyglutamine expansion toxicity.

An anti-CTLA-4 aptamer inhibits receptor function to overcome tumor resistance without damaging normal cells.

Optimized crystallization stabilizes rifaximin polymorphs, resolving physical property variations to enhance bioavailability.

Optimized pharmaceutical compositions minimize systemic side effects while extending shelf life through controlled release mechanisms.

Formula 1 compounds inhibit HIV-1 infectivity via Nef protein targeting, reducing drug resistance in antiretroviral therapy.

Adding ascorbic acid and optimizing secondary drying temperatures preserves mRNA integrity against oxidative degradation during lyophilization.

GelMA hydrogels encapsulate VH298-loaded exosomes to overcome poor water solubility and accelerate diabetic wound healing.

Pairing PI3-K inhibitors with MUC1 peptides disrupts survival signaling to kill multidrug-resistant tumors.

Targeting soluble adenylyl cyclase and EPAC pathways regulates melanosome pH, addressing the bottleneck of poorly understood pigment control mechanisms.

A zinc delivery agent with an amino acid induces selective vasodilation to improve cerebral and renal blood flow.

Neohesperidin extracts resolve the contradiction between natural plant sources and effective blood circulation by isolating specific active components.

NHE inhibitor compounds reduce systemic sodium and fluid levels via fecal excretion, avoiding renal impairment and systemic side effects.

Hydroxypropylthiazolidine carboxamide derivatives bind to the prostaglandin F2α receptor to inhibit uterine contractions.

Substituted thymoquinone derivatives bind and stabilize G-quadruplex DNA structures to inhibit telomerase activity.

Gamma-cyclodextrin oligomers sequester hydrophobic regions of misfolded proteins, reducing aggregation and inflammation while slowing neural function loss.

Machine learning classifiers analyze mutational spectra to detect HRD, resolving inconsistent measurement standards across diverse tumor types.

Soybean oil and ethanol mixture enhances oral absorption of testosterone, preventing liver inactivation to achieve effective blood levels.

A transdermal formulation delivers ibuprofen and gabapentin to peripheral nerve tissue for synergistic pain relief.

Alkoxy substituents on glucopyranosyl-substituted benzonitrile derivatives enhance SGLT2 inhibitory potency while maintaining selectivity over SGLT1.

CPVL inhibitor therapy treats skin cancer by adjusting dosage according to CPVL missense variants, addressing inadequate early detection.

Antiferromagnetic wüstite iron oxide nanoparticles conjugated with biocompatible capping agents provide high T1-weighted magnetic resonance imaging contrast.

Diarylhydrazide compounds inhibit androgen receptor transcriptional activity through non-ligand binding pocket modulation.

Modified norbixin compounds enhance ocular tropism and photo-protective activity to treat dry AMD.

FHSS hotspot device coordinates multiple peripheral units over distinct frequencies to enable simultaneous multimedia sessions.

Engineered STING agonist compounds overcome viral suppression mechanisms to enhance anti-tumor activity and therapeutic success rates.

Coordinating 3-bromopyruvate to a Pt(IV) center stabilizes the unstable glycolysis inhibitor for oral administration while reducing systemic toxicity.

Topical soft MEK inhibitors bypass systemic circulation to treat dermal neurofibromas while minimizing dose-limiting toxicity.

Substituted dihydropyridinones covalently bind BET proteins, resolving selectivity trade-offs that cause off-target toxicity.

Inducing MUC1 cleavage to generate MGFR mediators resolves insufficient stimulation effectiveness by dramatically increasing cell expansion rates.

Segmented nanolipogels synchronize release of hydrophobic and hydrophilic drugs, resolving mismatched kinetics in combination therapies.

Combining an MK2 inhibitor with CRISPR/Cas9-mediated BAALC knockout overcomes limited monotherapy efficacy in aggressive acute myeloid leukemia.

Segmented molecular design optimizes GLS1 inhibition and metabolic stability for cancer therapy.

Modified quinazoline compounds penetrate the blood-brain barrier to achieve therapeutic concentrations in brain tissue, treating EGFR mutant metastases.

A carboxyalkyl chitosan derivative with a zeta potential below -10 mV at pH 7.5 provides enhanced solubility in physiological conditions.

TH-4000 overcomes hypoxia-induced resistance by activating EGFR inhibition specifically within the tumor microenvironment.

Segmenting rare tumor tissue into single cells reveals oncogenic signatures, enabling targeted inhibition of BMI1 and PDGFRA.

Biocompatible protein carriers bind chemotherapeutic drugs to reduce toxicity to healthy tissues while maintaining tumor efficacy.

Substituted pyrazolopyrimidooxazine compounds displace unstable water molecules from the TYK2 pseudokinase binding pocket.

Chromatography purification isolates DHA-enriched phospholipid species to transport docosahexaenoic acid across the blood-brain barrier.

A sodium carboxymethyl cellulose and gossypol copolymer modifies neuroleptic response profiles.

A multi-strain probiotic formulation using Lactobacillus crispatus, gasseri, and johnsonii to inhibit pathogens.

Ganglioside formulations enhance muscle mass by stimulating protein synthesis while suppressing degradation enzymes in atrophic tissue.

A powdered composition of micronized cromolyn sodium and ibuprofen improves aerodynamic flow for inhalation.

Indazole compounds induce scleraxis gene expression, replacing invasive surgery with pharmacological tendon repair.

Lipophilic rectal suppository formulation releases isoflavonoids to maintain steady-state plasma concentrations.

A novel synthesis process for 3-substituted phenoxy pyridinone derivatives using modular cyclization and coupling reactions.

An antisense oligonucleotide mobilizes leukemia cells from bone marrow by inhibiting alpha4 integrin expression.

RNA decorated liposomes prevent leakage and degradation of water-soluble compounds by forming a stable hydrophilic shell around the vesicular core.

A gravity-driven mixing process encapsulates messenger RNA in liposomes using controlled fluid flow rates without mechanical pumps.

Multilayer films block gas permeation to maintain drug purity, solving single-layer leakage issues in prefilled infusion systems.